# Ford Worthy

> Ford Worthy is a Series A investor at Pappas Ventures backing Therapeutics and Biotechnology. See 2 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Pappas Ventures](https://shizune.co/investors/profile/pappas-ventures)
- Location: Durham, United States
- Total investments: 2
- Last investment: Mar 2014
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/in/fordworthy

Ford Worthy is a Series A investor at Pappas Ventures in Durham focused on Therapeutics and Biotechnology. Ford Worthy joined Pappas Capital as Partner and Senior Advisor in 2019.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Therapeutics | 1 | 50% |
| Biotechnology | 1 | 50% |
| Pharmaceutical | 1 | 50% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 50% |
| Series B | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Lumena Pharmaceuticals | Lumena Pharmaceuticals is developing oral therapeutics for rare liver diseases to improve liver function, relieve disease symptoms and dramatically impact patient health. The company’s clinical-stage product candidates carry a reduced risk of systemic toxicities by selectively targeting a transporter in the intestine and are designed to beminimally absorbed in the body. Lumena’s lead candidate, LUM001, has been extensively evaluated in other indications across 12 clinical studies in more than 1,400 subjects. Because of the extensive preclinical and clinical data package for a compound at this stage in development, LUM001 is positioned to rapidly progress through the clinic in pediatric and adult patients with several types of cholestatic liver disease. While Lumena’s primary focus is to develop novel treatments for patients with rare liver diseases, the company’s therapeutic approach also has promising potential in the treatment of metabolic diseases affecting the liver, a significant and growing health problem in children and adults. | $45M | Series B | Mar 11, 2014 |  |
| Lumena Pharmaceuticals | Lumena Pharmaceuticals is developing oral therapeutics for rare liver diseases to improve liver function, relieve disease symptoms and dramatically impact patient health. The company’s clinical-stage product candidates carry a reduced risk of systemic toxicities by selectively targeting a transporter in the intestine and are designed to beminimally absorbed in the body. Lumena’s lead candidate, LUM001, has been extensively evaluated in other indications across 12 clinical studies in more than 1,400 subjects. Because of the extensive preclinical and clinical data package for a compound at this stage in development, LUM001 is positioned to rapidly progress through the clinic in pediatric and adult patients with several types of cholestatic liver disease. While Lumena’s primary focus is to develop novel treatments for patients with rare liver diseases, the company’s therapeutic approach also has promising potential in the treatment of metabolic diseases affecting the liver, a significant and growing health problem in children and adults. | $23M | Series A | May 08, 2013 |  |

2 of 2 investments shown.

## Co-investors
- [RiverVest](https://shizune.co/investors/profile/rivervest) — VC Fund, 2 deals together
- [Adage Capital Management](https://shizune.co/investors/profile/adage-capital-management) — VC Fund, 1 deal together
- [Alta Partners](https://shizune.co/investors/profile/alta-partners) — VC Fund, 1 deal together
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund, 1 deal together
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 1 deal together
- [Sanofi Ventures](https://shizune.co/investors/profile/sanofi-genzyme-bioventures) — VC Fund, 1 deal together

## About Pappas Ventures

VC Fund · Durham, United States

Pappas Ventures provides investment in the life sciences sector.

5 contacts available at Pappas Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Eric W. Linsley | Partner | https://shizune.co/investors/profile/eric-w-linsley |
| Ford Worthy | Partner | https://shizune.co/investors/profile/ford-worthy |
| Franz Humer | Venture partner and Senior editor | https://shizune.co/investors/profile/franz-humer |
| Mike Grey | Venture Partner | https://shizune.co/investors/profile/mike-grey |
| Artthur M. Pappas | Founder, CEO & Managing General Partner | https://shizune.co/investors/profile/artthur-m-pappas |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Ford Worthy invest in?

Ford Worthy invests primarily in Therapeutics, Biotechnology and Pharmaceutical startups, most often at Series A and Series B stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Ford Worthy last invest?

The most recent investment recorded for Ford Worthy closed in Mar 2014. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co